File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3399/bjgpopen20X101127
- Scopus: eid_2-s2.0-85107903208
- PMID: 33172851
- WOS: WOS:001124719200012
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Lipid Levels And Major Adverse Cardiovascular Events In Patients Initiated On Statins For Primary Prevention: An International Population-based Cohort Study Protocol
Title | Lipid Levels And Major Adverse Cardiovascular Events In Patients Initiated On Statins For Primary Prevention: An International Population-based Cohort Study Protocol |
---|---|
Authors | |
Keywords | hydroxymethylglutaryl-CoA reductase inhibitors cholesterol major adverse cardiovascular events primary prevention cohort studies |
Issue Date | 2021 |
Publisher | Royal College of General Practitioners: Open Access Journals. The Journal's web site is located at https://bjgpopen.org |
Citation | BJGP Open, 2021, v. 5 n. 1, p. article no. bjgpopen20X101127 How to Cite? |
Abstract | Background: Clinical guidelines recommend specific targets for low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C) for primary prevention of cardiovascular disease (CVD). Furthermore, individual variability in lipid response to statin therapy requires assessment of the association in diverse populations.
Aim: To assess whether lower concentrations of LDL-C and non-HDL-C are associated with a reduced risk of major adverse cardiovascular events (MACE) in primary prevention of CVD.
Design & setting: An international, new-user, cohort study will be undertaken. It will use data from three electronic health record databases from three global regions: Clinical Practice Research Datalink, UK; PREDICT-CVD, New Zealand (NZ); and the Clinical Data and Analysis Reporting System, Hong Kong (HK).
Method: New statin users without a history of atherosclerotic CVD, heart failure, or chronic kidney disease, with baseline and follow-up lipid levels will be eligible for inclusion. Patients will be classified according to LDL-C (<1.4, 1.4–1.7, 1.8–2.5, and ≥2.6 mmol/l) and non-HDL-C (<2.2, 2.2–2.5, 2.6–3.3, and ≥3.4 mmol/l) concentrations 24 months after initiating statin therapy. The primary outcome of interest is MACE, defined as the first occurrence of coronary heart disease, stroke, or cardiovascular death. Secondary outcomes include all-cause mortality and the individual components of MACE. Sensitivity analyses will be conducted using lipid levels at 3 and 12 months after starting statin therapy.
Conclusion: Results will inform clinicians about the benefits of achieving guideline recommended concentrations of LDL-C for primary prevention of CVD. |
Persistent Identifier | http://hdl.handle.net/10722/289468 |
ISSN | 2023 Impact Factor: 2.5 2023 SCImago Journal Rankings: 0.982 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | BLAIS, JE | - |
dc.contributor.author | Akyea, R | - |
dc.contributor.author | Coetzee, A | - |
dc.contributor.author | Chan, AHY | - |
dc.contributor.author | Lau, WCY | - |
dc.contributor.author | Man, KCK | - |
dc.contributor.author | Harrison, J | - |
dc.contributor.author | Chan, EW | - |
dc.contributor.author | Beyene, KA | - |
dc.contributor.author | Wong, ICK | - |
dc.date.accessioned | 2020-10-22T08:13:06Z | - |
dc.date.available | 2020-10-22T08:13:06Z | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | BJGP Open, 2021, v. 5 n. 1, p. article no. bjgpopen20X101127 | - |
dc.identifier.issn | 2398-3795 | - |
dc.identifier.uri | http://hdl.handle.net/10722/289468 | - |
dc.description.abstract | Background: Clinical guidelines recommend specific targets for low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C) for primary prevention of cardiovascular disease (CVD). Furthermore, individual variability in lipid response to statin therapy requires assessment of the association in diverse populations. Aim: To assess whether lower concentrations of LDL-C and non-HDL-C are associated with a reduced risk of major adverse cardiovascular events (MACE) in primary prevention of CVD. Design & setting: An international, new-user, cohort study will be undertaken. It will use data from three electronic health record databases from three global regions: Clinical Practice Research Datalink, UK; PREDICT-CVD, New Zealand (NZ); and the Clinical Data and Analysis Reporting System, Hong Kong (HK). Method: New statin users without a history of atherosclerotic CVD, heart failure, or chronic kidney disease, with baseline and follow-up lipid levels will be eligible for inclusion. Patients will be classified according to LDL-C (<1.4, 1.4–1.7, 1.8–2.5, and ≥2.6 mmol/l) and non-HDL-C (<2.2, 2.2–2.5, 2.6–3.3, and ≥3.4 mmol/l) concentrations 24 months after initiating statin therapy. The primary outcome of interest is MACE, defined as the first occurrence of coronary heart disease, stroke, or cardiovascular death. Secondary outcomes include all-cause mortality and the individual components of MACE. Sensitivity analyses will be conducted using lipid levels at 3 and 12 months after starting statin therapy. Conclusion: Results will inform clinicians about the benefits of achieving guideline recommended concentrations of LDL-C for primary prevention of CVD. | - |
dc.language | eng | - |
dc.publisher | Royal College of General Practitioners: Open Access Journals. The Journal's web site is located at https://bjgpopen.org | - |
dc.relation.ispartof | BJGP Open | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | hydroxymethylglutaryl-CoA reductase inhibitors | - |
dc.subject | cholesterol | - |
dc.subject | major adverse cardiovascular events | - |
dc.subject | primary prevention | - |
dc.subject | cohort studies | - |
dc.title | Lipid Levels And Major Adverse Cardiovascular Events In Patients Initiated On Statins For Primary Prevention: An International Population-based Cohort Study Protocol | - |
dc.type | Article | - |
dc.identifier.email | Man, KCK: mkckth@hku.hk | - |
dc.identifier.email | Chan, EW: ewchan@hku.hk | - |
dc.identifier.email | Wong, ICK: wongick@hku.hk | - |
dc.identifier.authority | Chan, EW=rp01587 | - |
dc.identifier.authority | Wong, ICK=rp01480 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.3399/bjgpopen20X101127 | - |
dc.identifier.pmid | 33172851 | - |
dc.identifier.pmcid | PMC7960514 | - |
dc.identifier.scopus | eid_2-s2.0-85107903208 | - |
dc.identifier.hkuros | 316288 | - |
dc.identifier.volume | 5 | - |
dc.identifier.issue | 1 | - |
dc.identifier.spage | article no. bjgpopen20X101127 | - |
dc.identifier.epage | article no. bjgpopen20X101127 | - |
dc.identifier.isi | WOS:001124719200012 | - |
dc.publisher.place | United Kingdom | - |